May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Treatment of Conjunctival and Corneal Intraepithelial Neoplasia with Topical Interferon –2b in Conjunction with Ocular Surface Reconstruction Surgeries
Author Affiliations & Notes
  • Y. Inoue
    Department of Ophthalmology, Faculty Med Tottori Univ, Yonago, Japan
  • R. Shimoyama
    Department of Ophthalmology, Faculty Med Tottori Univ, Yonago, Japan
  • S. Takeda
    Department of Ophthalmology, Faculty Med Tottori Univ, Yonago, Japan
  • H. Katano
    Department of Ophthalmology, Faculty Med Tottori Univ, Yonago, Japan
  • D. Miyazaki
    Department of Ophthalmology, Faculty Med Tottori Univ, Yonago, Japan
  • Footnotes
    Commercial Relationships  Y. Inoue, None; R. Shimoyama, None; S. Takeda, None; H. Katano, None; D. Miyazaki, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3927. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Inoue, R. Shimoyama, S. Takeda, H. Katano, D. Miyazaki; Treatment of Conjunctival and Corneal Intraepithelial Neoplasia with Topical Interferon –2b in Conjunction with Ocular Surface Reconstruction Surgeries . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3927.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Conjunctival and corneal intraepithelial neoplasia (CIN) is one of the most common conjunctival malignancy. Basic management of CIN is surgical excision, and many adjunctive therapies have been used for the inhibition of recurrence, including radiation, cryotherapy, mitomycin–C, and 5–fluorouracil. These adjunctive therapies, however, are not suitable for the reconstruction of ocular surface after excision, because of cytotoxic nature of these treatments. Recently the effectiveness of topical interferon α–2b (INFα2b) against CIN has been reported. We evaluated the suitability of topical INFα2b and ocular reconstruction surgeries. Methods:Four patients were studied prospectively. After wide excision of tumor, we performed limbal allograft transplantation for two patients, and amniotic membrane transplantation for other two patients. After these operations, topical recombinant INFα2b was administered with 1 million IU / ml four times a day for one month. And they were followed clinically and photographically for evidence of tumor resolution and recurrences. All excised lesions were histologically proved to be carcinoma in situ in all cases. Results:All patients had complete resolution of the tumor. The mean follow–up time was 16.5 M (range 2 – 29M), and the recurrence of the tumor was not found. In one case, residual tumor had disappeared after 5 days’ instillation of interferon. Epithelial defect was observed in one case, however the defect was healed with no discontinuation of interferon eyedrops. One patient complained of slight nasopharyngeal pain, however serious side effects were not found in all cases. Conclusions:Topical INFα2b is safe and effective therapy and well fitted for ocular reconstruction surgeries to treat CIN and recover ocular surface integrity.

Keywords: tumors • transplantation • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×